The study published in the American Journal of Cancer Research shows that the Food and Drug Administration-approved medication crizotinib (also known by its name brand, Xalkori) is effective at inhibiting the growth of non-small cell lung cancer with the most common genetic mutations.
Existing Drug Shows Promise in Treating Most Prevalent Type of Lung Cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.